| Dr Daniel E Morganstern, MD | |
|
201 N Mountain Rd Ste 202, Plainville, CT 06062-1848 | |
| (860) 224-4408 | |
| (860) 827-3428 |
| Full Name | Dr Daniel E Morganstern |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 33 Years |
| Location | 201 N Mountain Rd Ste 202, Plainville, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003986852 | NPI | - | NPPES |
| 6979189 | Other | CIGNA | |
| 3118185 | Other | MASSHEALTH MA MEDICAID | |
| 766748 | Other | TUFTS | |
| 1003986852 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 060103 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hartford Hospital | Hartford, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Hospital | 2567366016 | 827 |
News Archive
The Salk Institute scientist who earlier discovered that enhancing the function of a single protein produced a mouse with an innate resistance to weight gain and the ability to run a mile without stopping has found new evidence that this protein and a related protein play central roles in the body's complex journey to obesity and offer a new and specific metabolic approach to the treatment of obesity related disease such as Syndrome X (insulin resistance, hyperlipidemia and atherosclerosis).
A letter in this weeks BMJ reports on how researchers are urging rural clinics in India to stop the superstitious practice known as 'branding treatment'.
Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.
Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.
Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs.
› Verified 2 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407806391 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000700 |
News Archive
The Salk Institute scientist who earlier discovered that enhancing the function of a single protein produced a mouse with an innate resistance to weight gain and the ability to run a mile without stopping has found new evidence that this protein and a related protein play central roles in the body's complex journey to obesity and offer a new and specific metabolic approach to the treatment of obesity related disease such as Syndrome X (insulin resistance, hyperlipidemia and atherosclerosis).
A letter in this weeks BMJ reports on how researchers are urging rural clinics in India to stop the superstitious practice known as 'branding treatment'.
Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.
Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.
Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs.
› Verified 2 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770696643 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000752 |
News Archive
The Salk Institute scientist who earlier discovered that enhancing the function of a single protein produced a mouse with an innate resistance to weight gain and the ability to run a mile without stopping has found new evidence that this protein and a related protein play central roles in the body's complex journey to obesity and offer a new and specific metabolic approach to the treatment of obesity related disease such as Syndrome X (insulin resistance, hyperlipidemia and atherosclerosis).
A letter in this weeks BMJ reports on how researchers are urging rural clinics in India to stop the superstitious practice known as 'branding treatment'.
Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.
Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.
Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs.
› Verified 2 days ago
| Entity Name | Starling Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467537290 PECOS PAC ID: 7517863749 Enrollment ID: O20031209000877 |
News Archive
The Salk Institute scientist who earlier discovered that enhancing the function of a single protein produced a mouse with an innate resistance to weight gain and the ability to run a mile without stopping has found new evidence that this protein and a related protein play central roles in the body's complex journey to obesity and offer a new and specific metabolic approach to the treatment of obesity related disease such as Syndrome X (insulin resistance, hyperlipidemia and atherosclerosis).
A letter in this weeks BMJ reports on how researchers are urging rural clinics in India to stop the superstitious practice known as 'branding treatment'.
Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.
Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.
Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs.
› Verified 2 days ago
| Entity Name | The Hospital Of Central Connecticut At New Britain General And Bradley |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063461481 PECOS PAC ID: 6507776564 Enrollment ID: O20040115000497 |
News Archive
The Salk Institute scientist who earlier discovered that enhancing the function of a single protein produced a mouse with an innate resistance to weight gain and the ability to run a mile without stopping has found new evidence that this protein and a related protein play central roles in the body's complex journey to obesity and offer a new and specific metabolic approach to the treatment of obesity related disease such as Syndrome X (insulin resistance, hyperlipidemia and atherosclerosis).
A letter in this weeks BMJ reports on how researchers are urging rural clinics in India to stop the superstitious practice known as 'branding treatment'.
Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.
Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.
Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel E Morganstern, MD 1290 Silas Deane Hwy Ste 102, Wethersfield, CT 06109-4337 Ph: (860) 972-3075 | Dr Daniel E Morganstern, MD 201 N Mountain Rd Ste 202, Plainville, CT 06062-1848 Ph: (860) 224-4408 |
News Archive
The Salk Institute scientist who earlier discovered that enhancing the function of a single protein produced a mouse with an innate resistance to weight gain and the ability to run a mile without stopping has found new evidence that this protein and a related protein play central roles in the body's complex journey to obesity and offer a new and specific metabolic approach to the treatment of obesity related disease such as Syndrome X (insulin resistance, hyperlipidemia and atherosclerosis).
A letter in this weeks BMJ reports on how researchers are urging rural clinics in India to stop the superstitious practice known as 'branding treatment'.
Patients beginning sunitinib treatment for advanced renal cell carcinoma should be warned that fatigue is likely to occur early, but that it is unlikely to worsen over the course of treatment, suggest US researchers in Cancer.
Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.
Studies of human tumor cells implanted in mice have shown that the abnormal activation of four genes drives the spread of breast cancer to the lungs.
› Verified 2 days ago
Derrick A Bailey, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 240 East St, Plainville, CT 06062 Phone: 860-747-4541 Fax: 860-793-1218 | |
Dr. Kevin Matthew Baran, M.D., M.P.H. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 120 W Main St, Plainville, CT 06062 Phone: 860-747-0411 | |
Dr. Helen Ifeyinwa Anaedo, M.D Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 201 N Mountain Rd, Department Of Endocrinology, Plainville, CT 06062 Phone: 860-229-8889 | |
Oosman Tariq, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 184 East St, Plainville, CT 06062 Phone: 860-747-5766 Fax: 860-747-2028 | |
Dr. Peter J Harris, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 184 East St, Plainville, CT 06062 Phone: 860-747-5766 Fax: 860-747-2028 | |
Ashley E Sanchez-mitchell, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 201 N Mountain Rd, Plainville, CT 06062 Phone: 860-827-4199 Fax: 860-827-4198 |